Testing apitegromab in babies with spinal muscular atrophy
Tests apitegromab in babies under 2 with spinal muscular atrophy.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate How Apitegromab Works in Subjects Who Are Less Than 2 Years Old and Have Spinal Muscular Atrophy
Key facts
- Where
- Ghent, Leuven, and Liège, BelgiumSee the 3 sites
- Phase
- Phase 2
Where in Belgium
- UZ GentGhent, BelgiumTaking people
- Uz Leuven Campus GasthuisbergLeuven, BelgiumTaking people
- CHR CitadelleLiège, BelgiumTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Scholar Rock, Inc.
- Trial code
- NCT07047144
- Record updated
- 2 October 2026
- Original description
This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects <2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score <55.Read full original descriptionShow less
A Phase 2, Double-Blind Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Apitegromab in Subjects <2 Years Old With Spinal Muscular Atrophy (SMA)
This double-blind, Phase 2, multiple-dose study will be conducted to evaluate the PK/PD, efficacy, safety, and tolerability of apitegromab in subjects <2 years old with 5q autosomal recessive SMA who have delayed motor milestones for their age attributed to SMA at the discretion of the Investigator or a Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND) score <55.
Inclusion: Is <2 years old at the time of the informed consent; Had a gestational age of ≥35 weeks and gestational body weight ≥2.0 kg at birth; Has confirmed diagnosis of 5q autosomal recessive SMA; Has confirmed presence of SMN2 gene copy(ies); Must have been treated with an approved SMN1-targeted therapy (ie, onasemnogene abeparvovec-xioi) or are continuing to be treated with an approved SMN2-targeted therapy (ie, nusinersen or risdiplam); Body weight for age is no less than 1st percentile based on the WHO Child Growth Standards at the Screening Visit; Has delayed motor milestones for age attributed to SMA at the discretion of the Investigator or a CHOP-INTEND score <55.
Exclusion: Major orthopedic issues such as severe scoliosis or severe contractures or interventional procedure, including spine or hip surgery, which is considered to have the potential to substantially limit the ability of the subject to be evaluated on any motor function outcome measures, within 6 months before Screening or anticipated during the study; Nutritional status that is not anticipated to be stable throughout the study or medical necessity for a gastric feeding tube, where most feeds are administered by this route; Any other physical limitations (eg, the subject requires cast for contractures) that would prevent the subject from undergoing motor function outcome measures throughout the study.